FdaApplication
NDA 022081
Identifiers
- fda_app_no: NDA022081
Properties
| Property | Value |
|---|---|
| applicant_name | GILEAD SCIENCES INC |
| application_type | NDA |
| approval_date | 2007-06-15 |
Revenue by product
LETAIRIS
| Period | Revenue |
|---|---|
| Q4 2023 | $36.0M |
| Q3 2023 | $36.0M |
| Q4 2022 | $61.0M |
| Q3 2022 | $43.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LETAIRIS | AMBRISENTAN | 5MG | TABLET;ORAL |
| LETAIRIS | AMBRISENTAN | 10MG | TABLET;ORAL |
2 products